#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Waldenstrom's macroglobulinaemia Immune-mediated myositis Soft tissue sarcoma Neuroendocrine carcinoma of the skin Myeloproliferative neoplasm Burkitt's lymphoma refractory Leukoencephalopathy Hyperchylomicronaemia Pulmonary fibrosis Soft tissue necrosis Pancreatic carcinoma Philadelphia positive chronic myeloid leukaemia T-cell type acute leukaemia Cholangiosarcoma Dedifferentiated liposarcoma More trials…

    Learn about Rare Diseases

    Haemophilia A with anti factor VIII – Treatment Waldenstrom’s macroglobulinaemia refractory – Basic Information Haemophagocytic lymphohistiocytosis Mitochondrial myopathy Hepatoblastoma – Basic Information Castleman’s disease – Basic Information Rhabdomyosarcoma – Trials in Disease Angelman’s syndrome – Life with Disease Cerebral arteriovenous malformation haemorrhagic – Diagnostics Primary biliary cholangitis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Linaclotide HSP-CAR19M Tiragolumab Neob Venlafaxine Gelatin Itacitinib Ucart22 Belimumab Abc-15Bo-116 Calcium Pantothenate Bp Rct2100 Jnj-81241459 Exidavnemab Dexchlorpheniramine Levosimendan Dolutegravir Sabestomig Dopamine Hydrochloride Datopotamab Deruxtecan More therapies…

    Learn about Your Condition

    Leiomyosarcoma Binge eating Triple negative breast cancer Testicular germ cell tumour Cerebral haemorrhage Insulin resistance Arteriovenous graft thrombosis Hyperoxaluria SAPHO syndrome Thrombocytosis Rheumatoid arthritis Postoperative wound infection Impaired gastric emptying Ectopic pregnancy Bladder cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Medullary thyroid cancer

  • A study of EP0031 and drug combination for patients with advanced cancers having changes in the RET gene

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Medullary thyroid cancer
    • Neoplasm malignant
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Ep0031
    • Carboplatin
    • Cisplatin
    France Germany Italy Poland Spain

  • Study Comparing Selpercatinib, Cabozantinib, and Vandetanib for Patients with Advanced RET-Mutant Medullary Thyroid Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Medullary thyroid cancer
    Investigated Drugs:
    • Selpercatinib
    • VANDETANIB
    • Cabozantinib
    Belgium Czechia France Germany Greece Italy +3

  • Comparison of two doses of cabozantinib (60 mg vs 140 mg) in patients with progressive metastatic medullary thyroid cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Medullary thyroid cancer
    Investigated Drugs:
    • Cabozantinib
    Croatia Hungary Poland Romania

  • Study on the Effects of Selpercatinib in Patients Aged 12 and Older with Advanced Solid Tumors with RET Gene Alteration

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Selpercatinib
    Denmark France Germany Italy Spain

  • Study on the Effects of Selpercatinib in Children with Advanced RET-Altered Solid Tumors or Primary Central Nervous System Tumors

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Selpercatinib
    Denmark France Germany Italy Spain

  • Study on Selpercatinib for Adults with Advanced or Metastatic Solid Tumors with RET Activation

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Papillary thyroid cancer
    • Colon cancer
    • Medullary thyroid cancer
    Investigated Drugs:
    • Selpercatinib
    France Italy Poland Spain

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!